Ajovy (fremanezumab-vfrm) is Teva’s injectable CGRP monoclonal antibody for migraine prevention, and it is the only one in its class that offers a quarterly dosing option alongside the standard monthly shot. That flexibility is the first thing most people hear about it, and it raises an obvious money question: does taking four shots a year instead of twelve cost less?
It does not, and the arithmetic is worth seeing. This guide prices Ajovy on both schedules using figures verified on September 2, 2026, anchored to Teva’s own January 1, 2026 list price as filed with a state price-disclosure program, plus two federal CMS datasets and live pharmacy pricing. It also covers the part that matters most to an uninsured reader, which is that Ajovy’s advertised $15 savings card is written to exclude you. This is a cost guide, not medical advice.
What Does Ajovy Cost Without Insurance?
Everything below is normalized to one month of prevention. One month is one 225 mg autoinjector or prefilled syringe. The quarterly dose is 675 mg, given as three 225 mg injections at one sitting, so a quarterly pack is divided by three for comparison. Prices verified September 2, 2026.
| Route | Low | Typical | High |
|---|---|---|---|
| Teva list price (WAC), 225 mg monthly dose | $755.15 | $755.15 | $755.15 |
| Teva list price, quarterly three-pack (per month) | $755.15 | $755.15 | $755.15 |
| Average retail cash price (SingleCare) | $1,043.89 | $1,043.89 | $1,043.89 |
| Named-chain retail cash price | $935.09 | $954.62 | $965.76 |
| Discount-card price | $689.95 | $749.27 | $894.15 |
| Pharmacy acquisition cost (CMS NADAC) | $761.14 | $762.23 | $762.88 |
| Ajovy Savings Card (commercial insurance only) | $15.00 | $15.00 | $15.00 |
| Teva Cares Foundation (income-qualified) | $0 | $0 | $0 |
The list price is the anchor, and it comes from a government filing rather than a press release. The Texas Department of State Health Services 2026 Annual WAC Report collects manufacturer-reported January 1, 2026 wholesale acquisition costs. Teva Pharmaceuticals USA reported $755.15 for both the 225 mg/1.5 mL autoinjector (NDC 51759-0202-10) and the prefilled syringe (NDC 51759-0204-10), and $2,265.46 for the autoinjector triple pack (NDC 51759-0202-22).
CMS’s National Average Drug Acquisition Cost file, effective August 19, 2026, independently corroborates that level. It prices the autoinjector at $508.15 per mL, which is $762.23 for a 1.5 mL dose, the syringe at $762.88, and the triple pack at $2,283.41, or $761.14 a month. Acquisition cost slightly above list is normal noise in survey-based NADAC data, and the two sources agree to within about 1%.
The retail figures come from SingleCare’s live Ajovy page, updated September 2, 2026: an average retail price of $1,043.89 per autoinjector and a headline card price of $689.95. GoodRx listed Ajovy the same day starting at $749.27, and Drugs.com’s price guide showed $782.41 for a single autoinjector and $2,331.45 for the three-pack. Named-chain card prices on SingleCare ranged from $509.01 to $894.15, but those move between visits and should be read as evidence of spread, not as a price you can count on.
What Drives the Price
Dosing schedule changes your cash flow, not your annual bill. Twelve monthly doses at $755.15 is $9,061.80 a year. Four quarterly packs at $2,265.46 is $9,061.84. Teva priced the triple pack at exactly three times the single dose, so the only thing quarterly buys you is fewer injection days and fewer trips to the pharmacy. If you are paying cash, quarterly also means finding $2,265 four times instead of $755 twelve times, which for many self-pay budgets is worse, not better.
There is no biosimilar. Ajovy is a biologic. The NADAC file lists a corresponding generic acquisition cost whenever one exists, and for every Ajovy NDC that field is empty as of August 19, 2026. Expect no cheap copy in the near term.
Autoinjector or syringe makes almost no difference. Teva reported the same $755.15 list price for both devices, and NADAC prices them within 65 cents of each other. Pick the device you are comfortable with rather than shopping on form.
Specialty pharmacy routing. CGRP injectables are frequently dispensed through specialty rather than retail pharmacies, which is a large part of why quoted prices swing by hundreds of dollars between chains. Call more than one.
No manufacturer cash-pay price. This is the structural difference between Ajovy and its two closest competitors. Teva does not publish a direct self-pay price for uninsured buyers, so the cheapest reliable cash route is a discount card at roughly $690 to $749, not a manufacturer program.
Cash Price vs. Insurance
Ajovy is a clear case where having the right insurance dominates every cash option, and where having no insurance leaves you paying near full freight.
CMS’s Medicare Part D Spending by Drug dashboard, published June 2026 with 2024 data, shows the program paid an average of $887.74 per Ajovy autoinjector claim and $880.04 per syringe claim, across 18,579 and 5,411 beneficiaries respectively. Those are plan-level payments rather than patient costs, and they sit above every cash figure in the table, which tells you the discount-card price of roughly $690 is genuinely competitive as raw pricing.
The commercial savings card is a different story. Teva advertises “as little as $15” per monthly or quarterly prescription, and the published terms confirm the number. The same document also states, in capital letters, that uninsured and cash-paying patients are not eligible, that patients on Medicare, Medicaid, VA, DoD or TRICARE are not eligible, and that cash discount cards cannot serve as the primary payer under the program. If you are reading this because you have no insurance, that card is not available to you, no matter how prominently it appears in search results.
One thing paying cash costs you: the money does not count toward a deductible or an out-of-pocket maximum. On a high-deductible plan that you expect to blow through anyway, running the claim can still be the better annual decision even when the cash price looks lower this month.
How to Pay Less
Apply to the Teva Cares Foundation first. Ajovy is one of only five medicines currently listed as available through the program. Eligibility requires U.S. residence, a valid prescription and, effective January 31, 2025, a total pre-tax household income at or below 300% of the federal poverty level. Teva states that for 2026 enrollment all patients are assessed under those guidelines, and that applicants under 150% of the federal poverty level must first submit proof of denial from Medicare’s Low-Income Subsidy program. Approved patients pay nothing, and there is no application fee.
Price the discount cards at every refill. The gap between the $1,043.89 average retail price and the $689.95 card price is about $354 a month, or more than $4,200 a year. Our GoodRx vs. SingleCare comparison explains how to check both in a couple of minutes. Because these prices are recalculated constantly, do it each time rather than assuming last month’s number holds.
Compare the whole class before committing. The four self-injected CGRP preventives list within about $30 a month of each other, but their cash routes are wildly different. Emgality is sold direct to self-pay patients starting at $299 a month, and Aimovig has a manufacturer-sponsored cash-pay price of $299 through a discount partnership. Vyepti is infused in a clinic and bills as a medical claim rather than a pharmacy one, which changes the math entirely.
Do not overlook the acute side of the budget. Prevention is only part of what migraine costs. Generic sumatriptan is a fraction of the price of branded rescue drugs like Nurtec, Ubrelvy and Qulipta, and swapping there frees up real money for the preventive.
Handle the visit and any facility bill separately. Getting the prescription written costs money too. Sanity-check a cash consult price with our fair price checker, and if the neurology clinic is hospital-owned, ask about charity care before the appointment. If a bill has already gone unpaid, our guide to negotiating medical bills covers what to say.
The Bottom Line
Ajovy lists at $755.15 a month as of January 2026, costs about $1,044 at an average retail counter, and lands near $690 to $749 with a discount card. Quarterly dosing does not save money, it just reshuffles when you pay. Over a year the two schedules differ by four cents at list.
For an uninsured reader the practical decision tree is short. If your household income is at or below 300% of the federal poverty level, apply to the Teva Cares Foundation and pay nothing. If it is not, price a discount card, and then price Emgality and Aimovig too, because both currently have manufacturer-backed cash routes at $299 a month that Ajovy does not match.